Correlation between Bone Turnover Markers and Bisphosphonates Treatment in Postmenopausal Osteoporosis

* Adnan Khan, Muhammad Hanif, Akhter Ahmed, Salman Habib, Shahid Komal
* Jr. Scientist, Clinical and Molecular labs, Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN)

Abstract
Objective: To find out the significance of bone turnover markers in management of osteoporotic patients and correlation to bisphosphonate treatments.
Design: Comparative, prospective, managerial
Setting: Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi.
Material and Methods: A total of 180 numbers of post-menopausal women were selected for the study by taking the verbal consent. Test patients were divided into five groups of 30 patients each on the basis of medicines they receive. Bisphosphonates, alendronates and risedronates, were prescribed to the patients under different brand names as fosamax, drate, osto, dronate and actonel. Serum osteocalcin, alkaline phosphatase and c-telopeptidase were selected as bone turnover markers and were assessed quarterly to find out the correlation between these markers and different treatment groups.
Results: The selected bone turnover markers i.e, alkaline phosphatase, osteocalcin&telopeptide were found to drop continuously at different rates in all patients undergoing treatment while in the control group these markers remained same with no significant changes throughout the year. The maximum fraction drop was found in telopeptide levels and minimum drop in alkaline phosphatase, while osteocalcin levels were lying in between.
Conclusion: Results showed that ALP is a good marker for indicating drug compliance but is weak for response prediction, at 3 and 6 months. Osteocalcin has slightly less sensitivity but better specificity therefore considered as moderate value marker. However c-telopeptide showed high sensitivity and specificity as early as 3 months and thus can be considered as an excellent and high value marker for predicting treatment response.
Keywords: Postmenopausal osteoporosis, bone turnover markers, bisphosphonates,

Introduction
Postmenopausal osteoporosis (PO) occurs as a common ailment with a spectrum ranging from asymptomatic bone loss to immobilize hip fracture. PO is reported to affect one third of the women as ageing population increases in many countries around the globe. The disease is generally characterized by reduction in bone mass, impaired bone strength and microscopic architectural changes in bones, resulting in bone fragility and subsequent increase in risk of fractures.

In the United States alone there are an estimated 1.5 million fractures per year because of osteoporosis\(^1\). Furthermore, it is predicted that the fracture occurrence in osteoporotic women will augment by the year 2025, yet very few will receive appropriate treatment because of the lack in reliance on diagnostic markers of clinical relevance\(^2,3\). The development of bone turnover markers (BTMs) has influenced the assessment and treatment of osteoporosis. A number of BTMs can now be determined clinically, and are generally divided into two categories as markers of bone formation and markers of bone resorption\(^4\). Bone formation markers reflect different phases of osteoblast in bone formation for instance alkaline phosphatase, abone formation marker, is reported to be involved in osteoid formation and mineralization. Similarly, osteocalcin is a protein product of osteoblast, odontoblast and hypertrophic
chondrocytes and its rate increases with bone formation rates. Conversely, most bone resorption markers are degradation products of collagen such as c-telopeptide. High levels of bone turnover markers are associated with 2-fold increased risk of osteoporotic fracture as well as suggestive to other metabolic bone diseases. BTMs are significant in management of osteoporosis treatment and thus identification of optimum treatment for an individual is of primary importance which could be achieved by estimating bone metabolism. Interestingly, BTMs predict changes in bone metabolism more rapidly than bone mineral density and therefore BTMs could be used as an indicator of response to osteoporosis treatment.

The primary goal of treatment for osteoporosis is to reduce the risk of bone fragility for which clinicians generally recommends bisphosphonates, the most common pharmacological treatment of postmenopausal osteoporosis, which are the analogs of naturally occurring pyrophosphate. It could be deduced from many experimental and clinical studies that biophosphonates increases bone turnover and bone resorption which subsequently helps in increased bone mass and mineralization however exact mechanism of action of biophosphonates remains to be resolved. Clodronate and etidronate were evaluated as the first-generation bisphosphonates but had not been approved as a therapeutic agent for osteoporosis. The second generation nitrogen-containing bisphosphonates, alendronates and risedronates, showed an increase bone mineral density in postmenopausal women with osteopenia or osteoporosis in randomized trials. They have been reported to reduce the incidence of hip, vertebral, and nonvertebral fracture by nearly 50 percent, particularly during the first year of treatment. A recent study showed that alendronate increased spine and hip bone mineral density slightly more than risedronate, although the clinical significance of this finding is uncertain. There are many studies that reported the use of BTMs as a derived endpoint of treatment value in clinical research and clinical trials of therapies, however the significance of BTMs in management of osteoporotic patients is not clearly defined and is debated in the present study.

**Materials & Methods**

**Subjects**

The study was carried out at Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN) Karachi for a period of one year. All the experiments were conducted as per guidelines under declaration of Helsinki. Patients visiting outpatient department were cautiously segregated by taking into account patients’ history of thyroid disorder, osteoporosis in the family and some other factors which may affect the bone turnover markers. A total of 180 numbers of postmenopausal women were selected for the study by taking the verbal consent out of which 150 patients were selected for therapy called as test while remaining 30 patients were selected as controls. Test patients were divided into five groups on the basis of medicines they receive. Each patient received single drug such that 30 numbers of patients were grouped together. Altogether 6 groups of 30 patients were intended wherein 5 groups were on different treatments and one was designated as control.

**Drugs & Dosing**

Bisphosphonates, alendronates and risedronates, were prescribed to the patients under different brand names as fosamax, drate, osto, dronate and actonel. The dosage was set according to the indications by Peters et al. Alendronates i-e fosamax, drate and osto were prescribed at a dose of 70mg weekly while risedronates, dronate and actonel, were given 35 mg weekly. The dosing was prescribed in fasting condition and patients were told to remain at fasting for 45 minutes after taking the medicine. Both alendronate and risedronate are profoundly well tolerated and were found effective in placebo controlled trials for the treatment of osteoporosis. The number of side effects of the bisphosphonate therapy included but not limited to ulceration of oesophagus, infrequent skin rashes, rare osteonecrosis of the jaw, rare cases of auditory hallucinations and visual disturbances etc.

**Serum Osteocalcin**

Osteocalcin ELISA kit supplied by Bioscience diagnostic Den mark was used for determination of osteocalcinin serum of patients. The test was carried out as per methodology described earlier. Two highly specific monoclonal antibodies against human osteocalcin were used as a principle. One antibody is specific for mid region present between 20-29 amino
acids while the other recognizes N-terminal region between amino acids 10-16, is a peroxidase conjugated antibody for detection. Samples, controls and standards were added into the streptavidin coated microtitre wells. A mixture of antibodies specific to mid and N terminal region were added followed by incubation for two hours. After incubation chromogenic substance was added and finally sulphuric acid was put in to stop the reaction. The concentration was measured at 450 nm.

**Serum alkaline phosphatase (ALP)**
Alkaline phosphatase consist of group of enzymes responsible for the catalytic hydrolysis of phosphate esters. Predominantly a change in ALP levels than normal is associated with various bone diseases however the specificity is yet to determine. A DGKC/kinetic method was used for the detection of AP via kit supplied by bioscience. The kinetic determination is done by a reaction in which p-nitrophenyl phosphate was catalyzed by ALP into p-nitrophenol and phosphate. The procedure used as per instructions by the supplier and the reference range was considered between 98-279 U/L.

**C-terminal telopeptide (CTX)**
The test was based on the principle described earlier. ELISA Kits supplied by Bioscience Diagnostics were used for quantification of degradation products of C-terminal telopeptides of type 1 collagen in the serum of subjects. The procedure was adopted as per instructions inside the supplied kit. Briefly, Standards, samples and control were added into the aptstriptavidin coated microtitre wells. After that a mixture of a biotinylated antibody and a peroxidase conjugated antibody is pipetted in the coated wells. A colored complex was formed as the crosslaps antigens, biotinylated antibody and peroxidase-conjugated antibody combined and attached to the streptavidin surface via the biotinylated antibody. The complex was then incubated for the hours at room temperature followed by washing of wells. A chromogenic substrate was then added further sulfuric acid was added to stop the colour reaction. The absorbance was measured at 450 nm.

**Statistical Analysis**
Statistical analysis was carried out using SPSS for windows version 12.0. The graphs were plotted in Microsoft Excel.

**Results**
Three selected bone turnover markers i.e, alkaline phosphatase, osteocalcin & telopeptide were found to drop continuously at different rates in all patients undergoing treatment while in the control group or untreated group these markers remained more or less same with no significant changes throughout the year. In five treatment groups ALP showed a significant and steady reduction. Osteotreatment group showed a reduction in ALP by –16.18%, -27.64%, -35.32% and – 43.82% at 3, 6, 9 and 12 months respectively. Treatment with drate, showed a decrease by -15.16%, -24.56%, -33.15% and -41.54% at 3, 6, 9 and 12 months respectively. Patients receiving a conel exhibited a fall in ALP levels by –18.17%, -27.49%, -35.90% and – 44.69% at 3, 6, 9 and 12 months respectively. Fosamax showed a decrease in ALP by -20.16%, -30.35%, - 40.00% and -49.33% at 3, 6, 9 and 12 months respectively. Similarly Dronate treatment showed decrease in ALP levels as the treatment progresses by -14.97%, -23.30%, -31.32% and -36.46% at 3, 6, 9 and 12 months respectively (Table 1 and Figure 1).

![Figure-1: Percentage drop in biochemical markers in therapy and control groups](image-url)
osteocalcin by -28.75%, -43.67%, -55.65% and -66.51% at 3, 6, 9 and 12 months respectively. Fosamax showed a decrease in osteocalcin by -29.38%, -44.53%, -57.54% and -72.79% at 3, 6, 9 and 12 months respectively. Dronate treatment showed reduction in osteocalcin levels by -19.27%, -31.42%, -40.46% and -49.07% at 3, 6, 9 and 12 months respectively (Table 1 and Figure 1). It can be deduced that the fall was maximum for fosamax. Osto, drate and actonel showed comparable levels of osteocalcin while the least drop was observed in case of Dronate. Control patients exhibit non-significant change in osteocalcin levels at all. In the present study telopeptide showed a significant reduction with all of the treatment groups. For instance in the osto group it showed a decrease by -40.71%, -54.39%, -63.26% and -72.14% at 3, 6, 9 and 12 months respectively. In Drate treated patients it dropped by -39.59%, -50.54%, -58.05% and -68.42% at 3, 6, 9 and 12 months respectively. Actonel treatment exhibited a fall by -39.13%, -48.41%, -54.94% and -66.95% at 3, 6, 9 and 12 months respectively. Treatment with fosamax showed a decrease in telopeptide levels by -44.35%, -55.91%, -65.17% and -76.63% at 3, 6, 9 and 12 months respectively. Lastly, dronate treatment showed the fall by -31.62%, -40.40%, -46.80% and -55.0% at 3, 6, 9 and 12 months respectively (Table 1 and Figure 1). It can be seen that fosamax showed maximum decrease. Results are somewhat comparable in case of osto, drate and actonel while minimum decrease in osteocalcin was observed in dronate treated group. The control showed non-significant change.

The graphical representations of the observations were presented in Figure 1 which demonstrates maximum fraction drop in telopeptide levels and minimum drop in alkaline phosphatase while osteocalcin lying in between. It is important to note that telopeptide levels dropped very instantly at 3 months and then moderately in the remaining period of treatment. The behaviors of BTMs in different treatment groups are summarized in Table 1.

### Table 1: Average percentage change in biochemical markers from baseline in treatment & control groups

<table>
<thead>
<tr>
<th>Time (months)</th>
<th>Osto</th>
<th>Drate</th>
<th>Dronate</th>
<th>Actonel</th>
<th>Fosamax</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>-19.94</td>
<td>-16.06</td>
<td>-19.27</td>
<td>-28.75</td>
<td>-29.38</td>
<td>-3.29</td>
</tr>
<tr>
<td>6</td>
<td>-35.71</td>
<td>-30.10</td>
<td>-31.42</td>
<td>-43.67</td>
<td>-44.53</td>
<td>-2.45</td>
</tr>
<tr>
<td>9</td>
<td>-46.27</td>
<td>-43.26</td>
<td>-40.46</td>
<td>-55.65</td>
<td>-57.54</td>
<td>-2.48</td>
</tr>
<tr>
<td>12</td>
<td>-56.86</td>
<td>-54.86</td>
<td>-49.07</td>
<td>-66.51</td>
<td>-76.63</td>
<td>-6.29</td>
</tr>
</tbody>
</table>

### Discussion

In postmenopausal osteoporosis the dose dependent bone turnover generally decreases with a range of bisphosphonates treatment\textsuperscript{14}. It was reported that bisphosphonates treatment induces significant decrease in bone resorption markers after one month while the decrease in bone formation markers is reported to be delayed, reaching at the peak post 6-12 months of therapy\textsuperscript{15}. The decrease in bone markers under antiresorptive therapy is strongly related to the increase in bone mass density (BMD)\textsuperscript{16}. Alendronate belongs to the group of bisphosphonates, reported to be used for the treatment of PO, showed a strong association between the changes in BTMs and the increase in BMD. There is plethora of evidence suggesting that BTMs can be used to scrutinize
treatment effectiveness within the first six months from the start of treatment when BMD alteration are still too small to be used clinically. Present study addresses this critical issue in a precise manner. Present study showed a sound drop in alkaline phosphatase (ALP) by -16.93%, -26.69%, -35.10% and -43.17% at 3, 6, 9 and 12 months respectively in the treatment group. In the control group there was little and non-significant change at all, i.e., -2.46%, during one year of the treatment. ALP is one of the BTMs, used as a marker of bone metabolism for examining patients during treatment. For example in the management of patients with metabolic bone disease such as Paget’s disease, osteoporosis, hyperparathyroidism and metastatic bone disease ALP might help to guide treatment choices for antiresorptive therapies and is also been used to confirm patient compliance in taking medications. ALP levels can also determine an earlier signal of response to treatment efficacy than bone density measurements. However there can be a few limitations in using ALP as a marker of bone turnover and these needs to be bear in mind. Many bone diseases influence a demineralization process and therefore many treatments are aimed at inhibiting bone resorption. Measurement of a bone resorption marker is thus more pertinent to the assessment of augmented bone loss with ailment. Moreover, the earliest changes in bone markers with antiresorptive therapy are seen with biochemical markers of bone resorption. It can be seen that changes in ALP may thus lag by a few weeks.

In our study a significant drop can be observed in osteocalcin levels by -22.68%, -37.09%, -48.63% and -60.02% at 3, 6, 9 and 12 months respectively in the treatment group. In control group there was little and non-significant change at all, i.e., -4.64%, in one year of treatment with bisphosphonates. A number of reasons make serum osteocalcin as a marker of bone formation. First and foremost is that serum osteocalcin is correlated with bone formation which was shown via histomorphometry or calcium kinetics. Secondly the synthesis of osteocalcin usually increases with mineralization and with progressive osteoblastic differentiation. Third reason could be deduced from early animal studies which reported that circulating osteocalcin ameliorated from new bone formation and not from breakdown of bone matrix. However, few advantages in using osteocalcin as a clinical index of bone turnover are its tissue specificity, its broad availability, and relatively small person to person difference. In general, serum levels of osteocalcin are elevated in patients with disease characterized by high bone turnover rate, and reflect the expected changes in bone formation following surgical or therapeutic intervention.

Present study reported that the degradation products of type I collagen has been the most promising BTM among three selected biomarkers. At present, C-telopeptide is divided into two categories depending on the choice of methods. These are CTX and ICTP, both immunoassays. The difference is due to recognition of different domains of the C-terminal telopeptide region of the α1 chain of type I collagen. Although there are few contrary reports in the literature, preliminary data from prospective reports indicate that certain bone markers, such as CTX, predict the risk of fracture as well as bone mineral density. It is quite possible that contradictory reports may have arose from studies that do not state well-defined sampling procedures, such as fasting status, time of collection, sample processing and storage conditions. Furthermore, the analytical methods have been improved with time and the more specific and precise automated methods have become available. Therefore to discover the clinical value of the markers in treatments which may not produce as large a change as seen, it is essential to reduce the least significant change of the marker. With added improvements of the assays a more accurate clinical picture will emerge. In the current study BTM telopeptide showed a significant and steady drop by -39.08 %, -49.93 %, -57.65 % and -67.83 % at 3, 6, 9 and 12 months respectively in the treatment group. In the control group there was a non-significant change i.e., -6.29 % during one year of treatment.

In a nut shell BTMs ALP, Osteocalcin and C-Telopeptide (CTX) were studied on a quarterly basis and it was revealed that ALP has a high sensitivity but a low specificity especially at 3 and 6 months. This showed that the ALP is a good for indicating drug compliance but is weak for response prediction, at 3
and 6 months. On the other hand osteocalcin has slightly less sensitivity but better specificity. Therefore the osteocalcin might be considered as moderate value marker which predicts the patients’ response to drugs. It is to be noted that the BTM telopeptide showed high sensitivity and specificity as early as 3 months and thus can be considered as an excellent and high value marker for predicting treatment response. The BTMs can be used for convincing prediction of response in bone mass during anti-resorptive therapy as early as 3 months. It was established in our study that the marker telopeptide most specific and sensitive among the three selected BTMs for prediction of individual response to treatment. BTM telopeptide exhibited a pronounced response to therapy with a low minimum significant change and values were showed as change from baseline at month 3 or 6 for optimal individual prediction of BMD response to treatment.

Conflict of interest
Authors declare no competing interest

References


<table>
<thead>
<tr>
<th>HISTORY</th>
<th>CONTRIBUTION OF AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Received:</td>
<td>Author</td>
</tr>
<tr>
<td>Date Sent for Reviewer:</td>
<td></td>
</tr>
<tr>
<td>Date Received Reviewers' Comments:</td>
<td></td>
</tr>
<tr>
<td>Date Received Revised manuscript:</td>
<td></td>
</tr>
<tr>
<td>Date Accepted:</td>
<td></td>
</tr>
</tbody>
</table>

**KEY FOR CONTRIBUTION OF AUTHORS:**
A. Conception, Synthesis and Planning of the research
B. Active Participation in active methodology
C. Interpretation, analysis and discussion